Abstract
Thromboxane A 2 (TXA 2 ) and prostacyclin (PGI 2 ) are two labile products formed from arachidonic acid by the way of cyclooxygenase. An overproduction of thromboxane A 2 has been detected in a series of diseases whereby this prostanoid is assumed to contribute to the underlying pathomechanisms by its potent stimulation of platelet aggregation and smooth muscle contraction. This increased TXA 2 biosynthesis is frequently accompanied by a stimulation of prostacyclin formation which is one of the most potent inhibitors of platelet aggregation and smooth muscle contraction. Therefore, TXA 2 prostaglandin endoperoxide H 2 receptor antagonists, thromboxane synthase inhibitors and drugs which combine both activities have been developed with the aim to suppress the formation and/or the action of thromboxane A 2 . Since prostacyclin has been demonstrated to counterbalance the pathological effects of TXA 2 , several PGI 2 agonists have also been developed. This review will highlight the evolution and some of the latest findings in the field of prostacyclin and thromboxane A 2 modulators mainly those which are under clinical evaluation or marketed.
Keywords: thromboxane A2 TXA2, prostacylin modulators, TXA2 biosynthesis, prostaglandin endoperoxide H2 receptor antagonists, thormboxane synthase inhibitors, TXSIs, TXA2 PGH2 receptor antagonists TXRAs, Prostanoid thromboxane A2 receptor antagonists, Non Prostanoid thromboxane A2 receptor antagonists, sulotroban, Combined thromboxane A2 receptor antagonists, prostaglandin D2, prostaglandin E2, prostaglandin H2, prostaglandin G2, prostaglandin F2
Current Medicinal Chemistry
Title: New Trends in Thromboxane and Prostacyclin Modulators
Volume: 7 Issue: 6
Author(s): Jean -Michel Dogne, Xavier de Leval, Jacques Delarge, Jean -Louis David and Bernard initial Masereel
Affiliation:
Keywords: thromboxane A2 TXA2, prostacylin modulators, TXA2 biosynthesis, prostaglandin endoperoxide H2 receptor antagonists, thormboxane synthase inhibitors, TXSIs, TXA2 PGH2 receptor antagonists TXRAs, Prostanoid thromboxane A2 receptor antagonists, Non Prostanoid thromboxane A2 receptor antagonists, sulotroban, Combined thromboxane A2 receptor antagonists, prostaglandin D2, prostaglandin E2, prostaglandin H2, prostaglandin G2, prostaglandin F2
Abstract: Thromboxane A 2 (TXA 2 ) and prostacyclin (PGI 2 ) are two labile products formed from arachidonic acid by the way of cyclooxygenase. An overproduction of thromboxane A 2 has been detected in a series of diseases whereby this prostanoid is assumed to contribute to the underlying pathomechanisms by its potent stimulation of platelet aggregation and smooth muscle contraction. This increased TXA 2 biosynthesis is frequently accompanied by a stimulation of prostacyclin formation which is one of the most potent inhibitors of platelet aggregation and smooth muscle contraction. Therefore, TXA 2 prostaglandin endoperoxide H 2 receptor antagonists, thromboxane synthase inhibitors and drugs which combine both activities have been developed with the aim to suppress the formation and/or the action of thromboxane A 2 . Since prostacyclin has been demonstrated to counterbalance the pathological effects of TXA 2 , several PGI 2 agonists have also been developed. This review will highlight the evolution and some of the latest findings in the field of prostacyclin and thromboxane A 2 modulators mainly those which are under clinical evaluation or marketed.
Export Options
About this article
Cite this article as:
Dogne -Michel Jean, Leval de Xavier, Delarge Jacques, David -Louis Jean and Masereel initial Bernard, New Trends in Thromboxane and Prostacyclin Modulators, Current Medicinal Chemistry 2000; 7 (6) . https://dx.doi.org/10.2174/0929867003374868
DOI https://dx.doi.org/10.2174/0929867003374868 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Stress in HIV Patients Receiving Antiretroviral Therapy
Current HIV Research ICT for Telemedicine and Health Care Innovation
Recent Patents on Biomedical Engineering (Discontinued) Soluble Epoxide Hydrolase, a Target with Multiple Opportunities for Cardiovascular Drug Discovery
Current Topics in Medicinal Chemistry Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry Resistin and Oxidative Stress in Non-Diabetic Obstructive Sleep Apnea Patients with Nocturnal Hypertension
Current Respiratory Medicine Reviews Research on the Pathological Mechanism and Drug Treatment Mechanism of Depression
Current Neuropharmacology Molecule of the Month
Current Topics in Medicinal Chemistry Calcium Homeostasis and Kinetics in Heart Failure
Medicinal Chemistry Effect of Antioxidant Extract from Cherries on Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Oral Antiplatelet Treatment in STEMI: Current Practice and Future Considerations
Current Pharmaceutical Design New Drugs for HDL-C Disorders: The Beginning
Current Medicinal Chemistry Nucleic Acid-Based Aptamers: Applications, Development and Clinical Trials
Current Medicinal Chemistry Social Determinants, Race, and Brain Health Outcomes: Findings from the Chicago Health and Aging Project
Current Alzheimer Research Antiarrhythmic Therapy on Prevention of Postoperative Atrial Fibrillation in Patients After Heart Surgery
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Prevention of Renal Complications Induced by Non- Steroidal Anti-Inflammatory Drugs
Current Medicinal Chemistry Metabolomics for Personalized Nutrition Research and Clinical Applications
Current Pharmacogenomics and Personalized Medicine An Overview of the Modulatory Effects of Oleic Acid in Health and Disease
Mini-Reviews in Medicinal Chemistry Sauropus androgynus Leaves for Health Benefits: Hype and the Science
The Natural Products Journal Editorial (Thematic Issue: Novel Targets and Biomarkers for Anti-atherosclerotic Therapy)
Current Pharmaceutical Design Signal Transduction of Steroidogenic Hormones to the Adrenal and Gonadal Mitochondria and the Possibilities for Combating Lipoid Congenital Adrenal Hyperplasia
Current Signal Transduction Therapy